Medifast, Inc. — Cyborg Score 3/10

Challenged
Health & Wellness / Weight Management Services

Strategic Profile

As of 2026, Medifast is moving from defining its business transformation strategy to executing on a new path to growth, leading to profitability as it becomes wholly focused on optimal metabolic health. Technology and personalization are core pillars of Medifast's strategy, driving deeper engagement and sustainable growth, with the company enhancing its digital tools and apps to improve customer engagement and connect consumers more seamlessly with their independent OPTAVIA coaches.

Cyborg Score Rationale

Medifast's independent active earning coaches fell to 16,100, a 40.6% year-over-year decline in Q4 2025. Full year 2026 revenue is projected between $270 million and $300 million with a loss per share between $1.55 and $2.75. The company cited rapid adoption of GLP-1 medications as one factor behind pressure on client acquisition.

Top Insights

  • Coach productivity turned positive year-over-year for the first time since 2022 in Q4 2025, signaling potential stabilization
  • Revenue per active earning coach improved 6.2% to $4,664 YoY, indicating improved efficiency of remaining coaches
  • Company holds $167.3M in cash with no debt, providing financial flexibility for strategic transformation
  • GLP-1 medications are disrupting traditional weight-loss coaching business model, requiring strategic pivot to metabolic health

Named Competitors

  • WW (Weight Watchers) Digital + Coaching — Points-based weight loss with hybrid coaching model
  • Nutrisystem Meal Plans — Pre-packaged meal delivery for weight management
  • USANA Nutritional Products — Multi-level nutrition and wellness platform

Recent Developments

  • (February 2026) Reported Q4 2025 results with $75.1M revenue and $1.70 per share loss; announced 2026 guidance targeting $270-300M revenue
  • (February 2026) Disclosed CEO transition and focus on metabolic health strategy; coach network down 40.6% YoY to 16,100
  • (December 2025) Weiss Ratings reaffirmed sell rating; Wall Street Zen upgraded stock from sell to hold in prior month

Open the full interactive Medifast, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →